Reported Earnings • May 18
First quarter 2026 earnings released: US$0.14 loss per share (vs US$0.35 loss in 1Q 2025) First quarter 2026 results: US$0.14 loss per share (improved from US$0.35 loss in 1Q 2025). Revenue: US$7.18m (down 14% from 1Q 2025). Net loss: US$4.28m (loss narrowed 59% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year. Annuncio • Mar 30
Retractable Technologies, Inc., Annual General Meeting, May 08, 2026 Retractable Technologies, Inc., Annual General Meeting, May 08, 2026. Reported Earnings • Mar 30
Full year 2025 earnings released: US$0.43 loss per share (vs US$0.41 loss in FY 2024) Full year 2025 results: US$0.43 loss per share (further deteriorated from US$0.41 loss in FY 2024). Revenue: US$38.3m (up 16% from FY 2024). Net loss: US$12.8m (loss widened 5.6% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Reported Earnings • Nov 16
Third quarter 2025 earnings released: EPS: US$0.01 (vs US$0.066 loss in 3Q 2024) Third quarter 2025 results: EPS: US$0.01 (up from US$0.066 loss in 3Q 2024). Revenue: US$10.1m (down 2.5% from 3Q 2024). Net income: US$313.4k (up US$2.29m from 3Q 2024). Profit margin: 3.1% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance. Board Change • Oct 23
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jul 24
Retractable Technologies, Inc. Announces Reduction in Manufacturing Workforce Retractable Technologies, Inc. reported that it has reduced its workforce by approximately 12.4%. The reduction is expected to save an estimated $1.6 million in annual wages and benefits, or approximately 8.6% of total estimated workforce costs. The expected savings is offset by one-time separation payments of approximately $56,000 to the affected workers. The reduction targets the Company's manufacturing and manufacturing support positions as the Company continues to balance its domestic manufacturing presence against its reliance on imported products and associated tariffs from its Chinese contract manufacturers. While contract manufacturers in China have historically produced most of the products the Company sells, the material financial impact of tariffs on Chinese imports has caused the Company to ramp-up its domestic production activities, while working to minimize the financial impact of the change. To the extent possible, the Company will continue to import only those products which it cannot make domestically and rely on its Little Elm facility to produce the remainder of its products. The Company is unable to predict future U.S. trade policy, or the potential impact it may have on the Company's ability to import products from China or other countries. Board Change • Jul 10
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Apr 11
Retractable Technologies, Inc. Announces Reduction in Workforce Retractable Technologies, Inc. reported that it has reduced its workforce by approximately 7%. The reduction is expected to save an estimated $1.6 million in annual wages and benefits, or approximately 7.8% of total estimated workforce costs. The expected savings is offset by one-time separation payments of approximately $300,000 to the affected workers. Approximately 72% of the targeted payroll reduction affects general and administrative functions, with the remainder coming from manufacturing or manufacturing support positions. The move comes as the Company continues to allocate more of its resources to increase its U.S. manufacturing capabilities and reduce reliance on products produced in China. While contract manufacturers in China have historically produced most of the products the Company sells, the material financial impact of tariffs on imports from China eliminates the Company’s ability to continue the practice. As a result, the Company will work to minimize its exposure to the tariffs and strategically import only those products which it cannot make domestically and rely on its Little Elm facility to produce the majority of its products. The Company is unable to predict future U.S. trade policy, or the potential impact it may have on the Company’s ability to import products from China or other countries. Annuncio • Mar 31
Retractable Technologies, Inc., Annual General Meeting, May 09, 2025 Retractable Technologies, Inc., Annual General Meeting, May 09, 2025. Reported Earnings • Mar 30
Full year 2024 earnings released: US$0.41 loss per share (vs US$0.24 loss in FY 2023) Full year 2024 results: US$0.41 loss per share (further deteriorated from US$0.24 loss in FY 2023). Revenue: US$33.0m (down 24% from FY 2023). Net loss: US$12.1m (loss widened 67% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 17
Third quarter 2024 earnings released: US$0.066 loss per share (vs US$0.14 loss in 3Q 2023) Third quarter 2024 results: US$0.066 loss per share (improved from US$0.14 loss in 3Q 2023). Revenue: US$10.3m (flat on 3Q 2023). Net loss: US$1.98m (loss narrowed 52% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 16
Second quarter 2024 earnings released: US$0.47 loss per share (vs US$0.13 loss in 2Q 2023) Second quarter 2024 results: US$0.47 loss per share (further deteriorated from US$0.13 loss in 2Q 2023). Revenue: US$6.03m (down 24% from 2Q 2023). Net loss: US$14.2m (loss widened 262% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. Reported Earnings • May 17
First quarter 2024 earnings released: EPS: US$0.012 (vs US$0.031 in 1Q 2023) First quarter 2024 results: EPS: US$0.012 (down from US$0.031 in 1Q 2023). Revenue: US$7.60m (down 31% from 1Q 2023). Net income: US$371.8k (down 60% from 1Q 2023). Profit margin: 4.9% (down from 8.5% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 01
Full year 2023 earnings released: US$0.24 loss per share (vs US$0.15 profit in FY 2022) Full year 2023 results: US$0.24 loss per share (down from US$0.15 profit in FY 2022). Revenue: US$43.6m (down 54% from FY 2022). Net loss: US$7.24m (down 250% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 23 percentage points per year, which is a significant difference in performance. Annuncio • Mar 30
Retractable Technologies, Inc., Annual General Meeting, May 10, 2024 Retractable Technologies, Inc., Annual General Meeting, May 10, 2024, at 10:00 Central Standard Time. Agenda: To vote on the election of three Class 2 Directors; and to consider other matters. Reported Earnings • Nov 17
Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.16 profit in 3Q 2022) Third quarter 2023 results: US$0.13 loss per share (down from US$0.16 profit in 3Q 2022). Revenue: US$10.3m (down 55% from 3Q 2022). Net loss: US$4.00m (down 175% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 54% per year whereas the company’s share price has fallen by 55% per year. Reported Earnings • Aug 15
Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.11 loss in 2Q 2022) Second quarter 2023 results: US$0.13 loss per share (further deteriorated from US$0.11 loss in 2Q 2022). Revenue: US$7.97m (down 44% from 2Q 2022). Net loss: US$3.93m (loss widened 6.1% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 17
First quarter 2023 earnings released: EPS: US$0.031 (vs US$0.23 in 1Q 2022) First quarter 2023 results: EPS: US$0.031 (down from US$0.23 in 1Q 2022). Revenue: US$11.0m (down 75% from 1Q 2022). Net income: US$932.9k (down 88% from 1Q 2022). Profit margin: 8.5% (down from 17% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 31
Full year 2022 earnings released: EPS: US$0.15 (vs US$1.65 in FY 2021) Full year 2022 results: EPS: US$0.15 (down from US$1.65 in FY 2021). Revenue: US$94.8m (down 50% from FY 2021). Net income: US$4.85m (down 91% from FY 2021). Profit margin: 5.1% (down from 30% in FY 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment deteriorated over the past week After last week's 15% share price decline to US$1.97, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 33x in the Medical Equipment industry in the US. Total returns to shareholders of 38% over the past three years. Reported Earnings • Nov 17
Third quarter 2022 earnings released: EPS: US$0.16 (vs US$0.19 in 3Q 2021) Third quarter 2022 results: EPS: US$0.16 (down from US$0.19 in 3Q 2021). Revenue: US$23.1m (down 37% from 3Q 2021). Net income: US$5.33m (down 18% from 3Q 2021). Profit margin: 23% (up from 18% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Board Change • Nov 17
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$2.05, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 32x in the Medical Equipment industry in the US. Total returns to shareholders of 55% over the past three years. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment improved over the past week After last week's 18% share price gain to US$2.28, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 32x in the Medical Equipment industry in the US. Total returns to shareholders of 81% over the past three years. Valuation Update With 7 Day Price Move • Sep 19
Investor sentiment deteriorated over the past week After last week's 18% share price decline to US$2.01, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 33x in the Medical Equipment industry in the US. Total returns to shareholders of 99% over the past three years. Board Change • Sep 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jun 07
Retractable Technologies, Inc. Reports Reduction in Workforce Retractable Technologies, Inc. reported that it has reduced its workforce by approximately 16% as a result of the substantial completion of its facility expansion efforts and the completion of U.S. government orders to provide its products for COVID-19 vaccination efforts. The staff reduction primarily affects its production, operations and logistics departments. The reduction will result in an overall annualized savings of approximately $2.1 million dollars, or 13% in annual payroll expense, and separation costs are expected to be approximately $200 thousand. The company expects that it will be able to maintain its current level of domestic production after the headcount reduction, and have significantly enhanced domestic production capacity upon completion of the expansion efforts. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • May 31
Investor sentiment improved over the past week After last week's 19% share price gain to US$4.63, the stock trades at a trailing P/E ratio of 3.4x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total returns to shareholders of 573% over the past three years. Reported Earnings • May 17
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: US$0.23 (down from US$0.53 in 1Q 2021). Revenue: US$44.7m (down 11% from 1Q 2021). Net income: US$7.56m (down 58% from 1Q 2021). Profit margin: 17% (down from 36% in 1Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 47%. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 11
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$3.63, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 33x in the Medical Equipment industry in the US. Total returns to shareholders of 438% over the past three years. Board Change • May 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Apr 22
Investor sentiment deteriorated over the past week After last week's 19% share price decline to US$3.64, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 38x in the Medical Equipment industry in the US. Total returns to shareholders of 406% over the past three years. Reported Earnings • Apr 02
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: US$1.65 (up from US$0.80 in FY 2020). Revenue: US$188.4m (up 130% from FY 2020). Net income: US$55.8m (up 110% from FY 2020). Profit margin: 30% (down from 33% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 47%. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 88% per year, which means it is significantly lagging earnings growth. Annuncio • Apr 01
Retractable Technologies, Inc., Annual General Meeting, May 10, 2022 Retractable Technologies, Inc., Annual General Meeting, May 10, 2022, at 10:00 Central Standard Time. Agenda: To consider the election of Three Class 2 Directors; and to consider an advisory vote to approve executive compensation. Reported Earnings • Nov 17
Third quarter 2021 earnings released: EPS US$0.19 (vs US$0.33 in 3Q 2020) The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$36.4m (up 34% from 3Q 2020). Net income: US$6.46m (down 41% from 3Q 2020). Profit margin: 18% (down from 41% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has increased by 134% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$10.03, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 48x in the Medical Equipment industry in the US. Total returns to shareholders of 1,290% over the past three years. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS US$0.31 (vs US$0.11 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: US$42.5m (up 267% from 2Q 2020). Net income: US$10.6m (up 195% from 2Q 2020). Profit margin: 25% (down from 31% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 132% per year but the company’s share price has increased by 148% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment improved over the past week After last week's 19% share price gain to US$12.02, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 56x in the Medical Equipment industry in the US. Total returns to shareholders of 1,384% over the past three years. Annuncio • Jun 08
Retractable Technologies, Inc. (NYSEAM:RVP) announces an Equity Buyback for $10 million worth of its shares. Retractable Technologies, Inc. (NYSEAM:RVP) announces a share repurchase program. Under the program, the company will repurchase up to $10 million worth of common stock. The program is valid until June 18, 2022. Reported Earnings • May 19
First quarter 2021 earnings released: EPS US$0.53 (vs US$0.005 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$50.1m (up 347% from 1Q 2020). Net income: US$17.9m (up US$17.7m from 1Q 2020). Profit margin: 36% (up from 1.3% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 138% per year but the company’s share price has only increased by 120% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Apr 24
Independent Director recently sold US$50k worth of stock On the 22nd of April, Walter Bigby sold around 5k shares on-market at roughly US$10.02 per share. In the last 3 months, they made an even bigger sale worth US$186k. Insiders have been net sellers, collectively disposing of US$5.1m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorated over the past week After last week's 17% share price decline to US$10.59, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 50x in the Medical Equipment industry in the US. Total returns to shareholders of 1,090% over the past three years. Reported Earnings • Apr 03
Full year 2020 earnings released: EPS US$0.80 (vs US$0.075 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$81.9m (up 96% from FY 2019). Net income: US$26.6m (up US$24.2m from FY 2019). Profit margin: 33% (up from 5.9% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 136% per year but the company’s share price has increased by 142% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment improved over the past week After last week's 15% share price gain to US$13.65, the stock is trading at a trailing P/E ratio of 27.3x, up from the previous P/E ratio of 23.7x. This compares to an average P/E of 50x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,275%. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$16.07, the stock is trading at a trailing P/E ratio of 32.2x, down from the previous P/E ratio of 38.2x. This compares to an average P/E of 56x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,637%. Recent Insider Transactions Derivative • Feb 21
Vice President of Sales Development notifies of intention to sell stock Russell Kuhlman intends to sell 13k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of February. If the sale is conducted around the recent share price of US$17.04, it would amount to US$223k. Since March 2020, Russell's direct individual holding has decreased from 46.00k shares to 13.10k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months. Annuncio • Feb 18
Retractable Technologies, Inc. Wins Firm Fixed Price and Cost Reimbursement Contract and Purchase Order Retractable Technologies, Inc. announced that on February 12, 2021, it was awarded a firm fixed price and cost reimbursement contract and purchase order by the Department of Health and Human Services to supply low dead space safety syringes. The base price for the contract and purchase order is $54,217,800 for the five-month base period of performance (February 15, 2021 to July 14, 2021). Such price includes both the fixed price for the products as well as cost reimbursement for freight. The terms of the contract allow for extensions at the option of the U.S. government for up to seven additional one-month periods. If all option periods are exercised, the value of the contract could increase by an additional $92,772,680, including the price of the products and freight reimbursement. For each period, the freight cost is estimated at approximately 25% of the overall price. Recent Insider Transactions • Feb 05
Independent Director recently sold US$186k worth of stock On the 2nd of February, Walter Bigby sold around 10k shares on-market at roughly US$18.55 per share. In the last 3 months, there was an even bigger sale from another insider worth US$3.0m. Insiders have been net sellers, collectively disposing of US$5.0m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment improved over the past week After last week's 29% share price gain to US$16.17, the stock is trading at a trailing P/E ratio of 32.4x, up from the previous P/E ratio of 25.2x. This compares to an average P/E of 53x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 2,087%. Is New 90 Day High Low • Jan 27
New 90-day high: US$15.69 The company is up 116% from its price of US$7.27 on 28 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. Recent Insider Transactions • Jan 22
Founder recently sold US$3.0m worth of stock On the 14th of January, Thomas Shaw sold around 210k shares on-market at roughly US$14.24 per share. This was the largest sale by an insider in the last 3 months. This was Thomas' only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Jan 20
Investor sentiment improved over the past week After last week's 22% share price gain to US$13.57, the stock is trading at a trailing P/E ratio of 27.2x, up from the previous P/E ratio of 22.3x. This compares to an average P/E of 54x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,798%. Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment deteriorated over the past week After last week's 23% share price decline to US$11.64, the stock is trading at a trailing P/E ratio of 23.3x, down from the previous P/E ratio of 30.1x. This compares to an average P/E of 51x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,696%. Is New 90 Day High Low • Dec 16
New 90-day high: US$15.00 The company is up 147% from its price of US$6.08 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 7.0% over the same period. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improved over the past week After last week's 31% share price gain to US$12.77, the stock is trading at a trailing P/E ratio of 25.6x, up from the previous P/E ratio of 19.5x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,751%. Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment improved over the past week After last week's 21% share price gain to US$12.09, the stock is trading at a trailing P/E ratio of 24.2x, up from the previous P/E ratio of 20x. This compares to an average P/E of 50x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,540%. Valuation Update With 7 Day Price Move • Dec 08
Market pulls back on stock over the past week After last week's 16% share price decline to US$9.75, the stock is trading at a trailing P/E ratio of 19.5x, down from the previous P/E ratio of 23.2x. This compares to an average P/E of 51x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,370%. Valuation Update With 7 Day Price Move • Dec 04
Market pulls back on stock over the past week After last week's 18% share price decline to US$10.00, the stock is trading at a trailing P/E ratio of 20x, down from the previous P/E ratio of 24.3x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,503%. Valuation Update With 7 Day Price Move • Dec 02
Market pulls back on stock over the past week After last week's 24% share price decline to US$10.61, the stock is trading at a trailing P/E ratio of 21.2x, down from the previous P/E ratio of 27.8x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,545%. Valuation Update With 7 Day Price Move • Nov 23
Market bids up stock over the past week After last week's 43% share price gain to US$12.01, the stock is trading at a trailing P/E ratio of 24x, up from the previous P/E ratio of 16.8x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,747%. Is New 90 Day High Low • Nov 18
New 90-day high: US$10.07 The company is up 31% from its price of US$7.67 on 20 August 2020. The American market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. Reported Earnings • Nov 18
Third quarter 2020 earnings released: EPS US$0.33 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$27.1m (up 133% from 3Q 2019). Net income: US$11.0m (up US$10.2m from 3Q 2019). Profit margin: 41% (up from 7.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has increased by 149% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 22
Market pulls back on stock over the past week After last week's 16% share price decline to US$7.71, the stock is trading at a trailing P/E ratio of 40.2x, down from the previous P/E ratio of 47.9x. This compares to an average P/E of 51x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,059%. 